Date

27th Feb 2012 - 28th Feb 2012

Location

Philadelphia, PA, USA, Philadelphia (see on map below)

Type

Conferences

URL

view event website

Organiser

Cypin Production LLC

Contact

Judy Tsui

judy@cypinproduction.com

+1 917 338 7778

Between now and 2016, prescription drugs with sales of $258 billion will lose their patents to generics. Today, generic drugs already represent 25 percent of worldwide pharmaceutical sales. The number is expected to increase considerably, especially in emerging markets like China, India, Russia, and Latin America, opening up investment opportunities for both pharmaceutical and generic companies.

Both generics and biosimilars represent substantial growth potential. The ability to offer high quality drugs at affordable prices is crucial to the success in emerging markets. Although biosimilars poses a greater potential return, the complexity involved in its development requires significantly more investment and time than generics manufacturing, forcing manufacturers to make careful selections on protein classes, building up new competencies, and developing strategic collaborations. On the other hand, off-patent drugs that carry a big Pharma name, also known as “branded generics”, are sizing up as they are trusted by overseas consumers to have a higher level of quality and effectiveness.

With the tremendous growth potential, now is the time to join the BRANDED GENERIC AND BIOSIMILARS conference to find out whether these opportunities for sales expansion is right for you. This two-day conference offers unprecedented insights from leading companies on how they plan to build the capabilities and strategies required to succeed in the branded generics and biosimilars arena overseas.